Literature DB >> 33442407

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields.

Shiyu Liu1,2,3, Qin Zhao1,2,3, Weiyan Shi1,2,3, Zhuangzhuang Zheng1,2,3, Zijing Liu1,2,3, Lingbin Meng4, Lihua Dong1,2,3, Xin Jiang1,2,3.   

Abstract

High-grade gliomas (HGGs) are the most common primary malignant brain tumors. They have a high degree of malignancy and show invasive growth. The personal treatment plan for HGG is based on the patient's age, performance status, and degree of tumor invasion. The basic treatment plan for HGG involves tumor resection, radiotherapy (RT) with concomitant temozolomide (TMZ), and adjuvant TMZ chemotherapy. The basic radiation technology includes conventional RT, three-dimensional conformal RT, intensity-modulated RT, and stereotactic RT. As our understanding of tumor pathogenesis has deepened, so-called comprehensive treatment schemes have attracted attention. These combine RT with chemotherapy, molecular targeted therapy, immunotherapy, or tumor-treating fields. These emerging treatments are expected to improve the prospects of patients with HGG. In the present article, we review the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG. © The author(s).

Entities:  

Keywords:  High-grade glioma; Immunotherapy; Molecular targeted drugs; Radiotherapy; Tumor-treating fields

Year:  2021        PMID: 33442407      PMCID: PMC7797642          DOI: 10.7150/jca.51107

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  111 in total

Review 1.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

Authors:  Normand Laperriere; Lisa Zuraw; Gregory Cairncross
Journal:  Radiother Oncol       Date:  2002-09       Impact factor: 6.280

2.  Conformation radiotherapy. Rotation techniques as applied to radiography and radiotherapy of cancer.

Authors:  S Takahashi
Journal:  Acta Radiol Diagn (Stockh)       Date:  1965

3.  Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.

Authors:  Hugo Câmara-Costa; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Colin Kennedy; Kim Bull; Gabriele Calaminus; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-17       Impact factor: 7.038

4.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Authors:  Jing Zeng; Alfred P See; Jillian Phallen; Christopher M Jackson; Zineb Belcaid; Jacob Ruzevick; Nicholas Durham; Christian Meyer; Timothy J Harris; Emilia Albesiano; Gustavo Pradilla; Eric Ford; John Wong; Hans-Joerg Hammers; Dimitris Mathios; Betty Tyler; Henry Brem; Phuoc T Tran; Drew Pardoll; Charles G Drake; Michael Lim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-22       Impact factor: 7.038

Review 5.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Ruth Garside; Gabriel Rogers; Ken Stein; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

6.  Incidence of gliomas by anatomic location.

Authors:  Suvi Larjavaara; Riitta Mäntylä; Tiina Salminen; Hannu Haapasalo; Jani Raitanen; Juha Jääskeläinen; Anssi Auvinen
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

7.  Acceptance and compliance of TTFields treatment among high grade glioma patients.

Authors:  Julia Onken; Franziska Staub-Bartelt; Peter Vajkoczy; Martin Misch
Journal:  J Neurooncol       Date:  2018-04-11       Impact factor: 4.130

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

Authors:  S A Toms; C Y Kim; G Nicholas; Z Ram
Journal:  J Neurooncol       Date:  2018-12-01       Impact factor: 4.130

10.  Hyperfractionated and hypofractionated radiation therapy for human malignant glioma xenograft in nude mice.

Authors:  M Hasegawa; H Niibe; N Mitsuhashi; M Yamakawa; S Kato; M Furuta; T Kazumoto; K Hayakawa; Y Nakazato
Journal:  Jpn J Cancer Res       Date:  1995-09
View more
  3 in total

1.  Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment.

Authors:  Xiangming Cai; Feng Yuan; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

Review 2.  Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms.

Authors:  Shiyu Liu; Lihua Dong; Weiyan Shi; Zhuangzhuang Zheng; Zijing Liu; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

3.  Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis.

Authors:  Yongchao Zhang; Shichao Chen; Hualei Chen; Shanshan Chen; Zhen Li; Enshan Feng; Wei Li
Journal:  Front Neurol       Date:  2022-01-04       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.